HEE-JIN JANG to Mesothelioma
This is a "connection" page, showing publications HEE-JIN JANG has written about Mesothelioma.
Connection Strength
1.431
-
Inhibition of Cyclin Dependent Kinase 4/6 Overcomes Primary Resistance to Programmed Cell Death 1 Blockade in Malignant Mesothelioma. Ann Thorac Surg. 2022 11; 114(5):1842-1852.
Score: 0.626
-
Soluble mesothelin-related peptide as a prognosticator in pleural mesothelioma patients receiving checkpoint immunotherapy. J Thorac Cardiovasc Surg. 2025 04; 169(4):1082-1095.e4.
Score: 0.193
-
A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma. Clin Cancer Res. 2023 02 01; 29(3):548-559.
Score: 0.172
-
Activation of Adaptive and Innate Immune Cells via Localized IL2 Cytokine Factories Eradicates Mesothelioma Tumors. Clin Cancer Res. 2022 12 01; 28(23):5121-5135.
Score: 0.170
-
Prognostic Role of Programmed Cell Death 1 Ligand 1 in Resectable Pleural Mesothelioma. Ann Thorac Surg. 2021 11; 112(5):1575-1583.
Score: 0.148
-
Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma. JCI Insight. 2018 04 05; 3(7).
Score: 0.123